Form 4: Intellia Therapeutics EVP, Chief Medical Officer Lebwohl Reports Stock and Option Grants

David Lebwohl, EVP and Chief Medical Officer of Intellia Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On March 1, 2025, David Lebwohl, the EVP and Chief Medical Officer of Intellia Therapeutics, acquired 43,200 shares of common stock through restricted stock units and was granted options to purchase 61,714 shares of common stock.
• The restricted stock units represent a contingent right to receive one share of Intellia common stock for each unit.
• The stock options have an exercise price of $10.09 and expire on February 28, 2035.
• 33% of the options vest on January 1, 2026, with the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
• Following these transactions, Lebwohl directly owns 130,866 shares of Intellia common stock and options to purchase 61,714 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of restricted stock units and stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule of the stock options incentivizes long-term commitment from the executive.

Industry Context

Stock grants and options are common compensation practices in the biotechnology industry to attract and retain key talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, like the one described (33% after one year, then monthly), are typical to incentivize long-term commitment.
• Companies like CRISPR Therapeutics and Editas Medicine, which are direct competitors of Intellia, also utilize stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they align executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates